Pharmaceutical and biotech shares have recently suffered declines, but most of them have risen compared to early this year, stock market data showed Tuesday.
Among 54 pharmaceutical and biotech firms listed on KOSDAQ, 43 companies’ closing prices on Monday were higher than those on Jan. 2. The rest 11 fell.
Sam Chun Dang Pharm enjoyed the most substantial stock price gain, with its shares soaring by 157.3 percent to 47,350 won ($43.9) from 18,400 won during the cited period.
Anterogen came next with 102 percent stock price growth from 57,000 won to 115,200 won.
Other big gainers were EyeGene with a 54.4 percent rise from Jan. 2 to Monday, Nature Cell with 50 percent, Sam-A Pharm with 44.7 percent, Prostemics with 44.5 percent, Alteogen with 43.8 percent, Korean Drug with 42.5 percent, GL PharmTech with 41.8 percent, DHP Korea with 41.7 percent, Celltrion Pharm with 41.4 percent, and Genexine with 41 percent.
On the other hand, GenoFocus stocks suffered the steepest drop, plunging by 40.2 percent to 12,650 won on Monday from 21,150 won on Jan. 2.
CHA Biotech stocks also nosedived by 26.7 percent to 21,450 won from 29,250 won during the same period.
Other big losers were Kolon Life Science with a 25.6 percent fall, Pharma Research Products with 24 percent, Celltrion HealthCare with 23.2 percent, Kolon TissueGene with 21.3 percent, Qurient with 19.6 percent, SillaJen with 18.7 percent, CMG Pharma with 14.9 percent, Curocom with 9.3 percent, and Humedix with 7.6 percent.
Celltrion HealthCare has become the largest company in KOSDAQ with the market cap reaching 11.26 trillion won after Celltrion moved to the main bourse KOSPI.
SillaJen ranks second with 5.7 trillion won, followed by Medytox’s fourth-ranking with 3.7 trillion won. ViroMed is at the sixth with 3.3 trillion won, Celltrion Pharm at the ninth with 3.1 trillion won, and Kolon TissueGene at the 10th with 2.6 trillion won.
<© Korea Biomedical Review, All rights reserved.>